International Clinical Trial: A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07728188) titled 'A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: AbbVie

Condition: Relapsed or Refractory Multiple Myeloma

Intervention: Drug: Etentamig Drug: Pomalidomide Drug: Daratumumab Drug: Dexamethasone Drug: Carfilzomib

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First E...